Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir.

Antiviral research - 1 Oct 2005

Doyon Louise, Tremblay Sonia, Bourgon Lise, Wardrop Elizabeth, Cordingley Michael G

Abstract excerpt

Tipranavir is a novel, non-peptidic protease inhibitor, which possesses broad antiviral activity against multiple protease inhibitor-resistant HIV-1. Resistance to this inhibitor however has not yet been well described. HIV was passaged for 9 months in culture in the presence of tipranavir to select HIV with a drug-resistant phenotype. Characterization of the selected variants revealed that the first mutations to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Tumor-Associated, Carbohydrate
Share to Gene Products, gag

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Protease

Share to Immunoglobulins

Share to Jurkat Cells

Share to Protease Inhibitors

Share to Pyrones

Share to Serial Passage

Source

Identifiers

PMID: 16122817
DOI: 10.1016/j.antiviral.2005.07.003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir.PMID 16122817Read ↗

Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir.Semantic proximity Read ↗

Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples.Semantic proximity Read ↗

Food and Drug Administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patients.Semantic proximity Read ↗

Tipranavir.Semantic proximity Read ↗

Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors.Semantic proximity Read ↗

Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients.Semantic proximity Read ↗

Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitors.Semantic proximity Read ↗

Successful virological outcome in an HIV-infected individual with a three-class resistant variant and an insertion in the protease genome with a Tipranavir based regimen.Semantic proximity Read ↗

Tipranavir: a ritonavir-boosted protease inhibitor.Semantic proximity Read ↗

Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy.Semantic proximity Read ↗

Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug.Semantic proximity Read ↗

Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.